IP Library Granted Patent US 12,582,621
Granted Patent B2
US 12,582,621 · App. 18/009,450 · Granted Mar 24, 2026

Compositions and methods for delivering pharmaceutical agents

Inventors: Heidi M. Mansour (Tucson, AZ); Rick G. Schnellmann (Tucson, AZ); David Encinas (Tucson, AZ)
Assignee: Arizona Board of Regents on Behalf of the Universityof Arizona
A61K31/185A61K9/0014A61K9/4816A61K47/36A61P17/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,582,621
App. No.
18/009,450
Granted
Mar 24, 2026
Kind
B2
Abstract

Provided herein are compositions and methods for delivering pharmaceutical agents. In particular, provided herein are hydrogel formulations of suramin for use in wound healing, wound prevention, and other applications.

Claims (17)

1 . A composition, comprising: suramin encapsulated in a crosslinked polymeric hydrogel comprising chitosan or carboxymethyl chitosan and poloxamer, wherein the composition is formulated for topical administration.

2 . The composition of claim 1 , wherein said crosslinked hydrogel is chemically physically, or oxidatively crosslinked.

3 . The composition of claim 1 , wherein said hydrogel further comprises a crosslinker.

4 . The composition of claim 3 , wherein said crosslinker is selected from the group consisting of glutaraldehyde, genipin, palladium cation, diisocyanate, and acrylic acid.

5 . The composition of claim 1 , wherein said chitosan is crosslinked in the presence of sodium bicarbonate.

6 . The composition of claim 5 , wherein said chitosan is crosslinked with sodium bicarbonate and genipin.

7 . The composition of claim 6 , wherein said sodium bicarbonate is present in said hydrogel at a concentration of 0.1 to 0.5M.

8 . The composition of claim 7 , wherein said sodium bicarbonate is present in said hydrogel at a concentration of 0.2 M.

9 . The composition of claim 6 , wherein said genipin is present in said hydrogel at a concentration of 1 to 3% by weight.

10 . The composition of claim 1 , wherein said chitosan is at a concentration of 0.5 to 5% w/v in said hydrogel.

11 . A method of treating a wound in a subject, comprising:

administering the composition of claim 1 to a subject with a wound under conditions such that said wound heals.

12 . The method of claim 11 , wherein said wound is selected from the group consisting of an acute wound and a chronic wound and ulcer.

13 . The method of claim 11 , wherein said subject has diabetes or mucositis.

14 . The method of claim 11 , further comprising administering an additional treatment for said wound.

15 . The method of claim 14 , wherein said additional treatment is selected from the group consisting of an antibiotic and a pain reliever.

16 . A method of reducing the likelihood of developing a wound caused by radiation therapy, comprising: topically administering the composition of claim 1 to a subject at risk of developing a wound under conditions such that the likelihood of developing said wound is reduced, wherein said composition is administered prior to radiation therapy.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2022
From: MANSOUR, HEIDI M.; SCHNELLMANN, RICK G.; ENCINAS, DAVID
To: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
Reel/Frame 062052/0112 →
Continuity (2)
Provisional Application 63037698 · Jun 11, 2020
Related Publication 20230225998A1 · Jul 20, 2023
References Cited (22)
US 20060002974A1 · Pacetti et al. · 2006 [cited by applicant]
US 20070191937A1 · Hossainy · 2007 [cited by examiner]
US 20110125287A1 · Hotter et al. · 2011 [cited by applicant]
US 20170360912A1 · Lerouge · 2017 [cited by examiner]
CN 106344496A · 2017 [cited by examiner]
WO WO2010009335 · 2010 [cited by applicant]
WO WO2016036823 · 2016 [cited by applicant]
WO WO2016036823A2 · 2016 [cited by examiner]
WO WO2019084290A1 · 2019 [cited by examiner]
Fattahpour et al (International Journal of Biological Macromolecules, Feb. 2020, vol. 151, pp. 220-229) (Year: 2020). [cited by examiner]
Wahba (Biotechnology Progress, Mar./Apr. 2018, vol. 34, pp. 347-361) (Year: 2018). [cited by examiner]
Patenall et al (International Journal of Molecular Sciences, 2024, vol. 25, pp. 1-18) (Year: 2024). [cited by examiner]
Sklar et al (The Journal of Urology, 1993, vol. 150, pp. 1526-1532) (Year: 1993). [cited by examiner]
CN-106344496-A (Google English translation, downloaded Apr. 2025) (Year: 2025). [cited by examiner]
Bartkowiak et al., Surface properties and morphology of selected polymers and their blends designed to mucoadhesive dosage forms, Reactive and Functional Polymers, 118: Oct. 19, 2017. [cited by applicant]
Brako et al., Mucoadhesion of Progesterone-Loaded Drug Delivery Nanofiber Constructs, ACS applied materials & interfaces, 10(16):13381-13389 2018. [cited by applicant]
Chai, Q. Hydrogels for Biomedical Applications: Their Characteristics and the Mechanisms behind Them, Gels 2017, 3, 6, pp. 1-15. [cited by applicant]
Dupre, et al., Suramin protects from cisplatin-induced acute kidney injury, Am. J. Physiol. Renal Physiol. Feb. 2016. 1; 310(3):F248-58. [cited by applicant]
International Search Report & Written Opinion, International Patent Application No. PCT/US2021/036980, mailed Sep. 8, 2021, 9 pages. [cited by applicant]
Korrapati, et al., Diabetes-Induced Renal Injury in Rats is Attenuated by Suramin, J. Pharmacol. Exp. Ther. Oct. 2012; 343(1):34-43. [cited by applicant]
Korrapati, et al., Suramin: A Potential Therapy for Diabetic Nephropathy, PLoS One Sep. 2013. 9, 8(9):e73655. [cited by applicant]
Liu et al., Smart gelation of chitosan solution in the presence of NaHCO3 for injectable drug delivery system, Int J Pharm. Jul. 29, 2011;414(1-2):6-15. [cited by applicant]